---
layout: model
title: Detect Drug Chemicals
author: John Snow Labs
name: ner_drugs
date: 2021-03-31
tags: [ner, clinical, licensed, en]
task: Named Entity Recognition
language: en
edition: Spark NLP for Healthcare 3.0.0
spark_version: 3.0
supported: true
article_header:
type: cover
use_language_switcher: "Python-Scala-Java"
---

## Description

Pretrained named entity recognition deep learning model for Drugs. The SparkNLP deep learning model (MedicalNerModel) is inspired by a former state of the art model for NER: Chiu & Nicols, Named Entity Recognition with Bidirectional LSTM-CNN.

## Predicted Entities

``DrugChem``.

{:.btn-box}
<button class="button button-orange" disabled>Live Demo</button>
[Open in Colab](https://colab.research.google.com/github/JohnSnowLabs/spark-nlp-workshop/blob/master/tutorials/Certification_Trainings/Healthcare/1.Clinical_Named_Entity_Recognition_Model.ipynb){:.button.button-orange.button-orange-trans.co.button-icon}
[Download](https://s3.amazonaws.com/auxdata.johnsnowlabs.com/clinical/models/ner_drugs_en_3.0.0_3.0_1617209727819.zip){:.button.button-orange.button-orange-trans.arr.button-icon}

## How to use



<div class="tabs-box" markdown="1">
{% include programmingLanguageSelectScalaPythonNLU.html %}
```python
...
word_embeddings = WordEmbeddingsModel.pretrained("embeddings_clinical", "en", "clinical/models")\
.setInputCols(["sentence", "token"])\
.setOutputCol("embeddings")
clinical_ner = MedicalNerModel.pretrained("ner_drugs", "en", "clinical/models") \
.setInputCols(["sentence", "token", "embeddings"]) \
.setOutputCol("ner")
...

nlpPipeline = Pipeline(stages=[document_assembler, sentence_detector, tokenizer, word_embeddings, clinical_ner, ner_converter])

model = nlpPipeline.fit(spark.createDataFrame([["The human KCNJ9 (Kir 3.3, GIRK3) is a member of the G-protein-activated inwardly rectifying potassium (GIRK) channel family. Here we describe the genomicorganization of the KCNJ9 locus on chromosome 1q21-23 as a candidate gene forType II diabetes mellitus in the Pima Indian population. The gene spansapproximately 7.6 kb and contains one noncoding and two coding exons separated byapproximately 2.2 and approximately 2.6 kb introns, respectively. We identified14 single nucleotide polymorphisms (SNPs), including one that predicts aVal366Ala substitution, and an 8 base-pair (bp) insertion/deletion. Ourexpression studies revealed the presence of the transcript in various humantissues including pancreas, and two major insulin-responsive tissues: fat andskeletal muscle. The characterization of the KCNJ9 gene should facilitate furtherstudies on the function of the KCNJ9 protein and allow evaluation of thepotential role of the locus in Type II diabetes.BACKGROUND: At present, it is one of the most important issues for the treatment of breast cancer to develop the standard therapy for patients previously treated with anthracyclines and taxanes. With the objective of determining the usefulnessof vinorelbine monotherapy in patients with advanced or recurrent breast cancerafter standard therapy, we evaluated the efficacy and safety of vinorelbine inpatients previously treated with anthracyclines and taxanes."]]).toDF("text"))

results = model.transform(data)
```
```scala
...
val word_embeddings = WordEmbeddingsModel.pretrained("embeddings_clinical", "en", "clinical/models")
.setInputCols(Array("sentence", "token"))
.setOutputCol("embeddings")
val ner = MedicalNerModel.pretrained("ner_drugs", "en", "clinical/models")
.setInputCols(Array("sentence", "token", "embeddings")) 
.setOutputCol("ner")
...

val pipeline = new Pipeline().setStages(Array(document_assembler, sentence_detector, tokenizer, word_embeddings, ner, ner_converter))

val data = Seq("The human KCNJ9 (Kir 3.3, GIRK3) is a member of the G-protein-activated inwardly rectifying potassium (GIRK) channel family. Here we describe the genomicorganization of the KCNJ9 locus on chromosome 1q21-23 as a candidate gene forType II diabetes mellitus in the Pima Indian population. The gene spansapproximately 7.6 kb and contains one noncoding and two coding exons separated byapproximately 2.2 and approximately 2.6 kb introns, respectively. We identified14 single nucleotide polymorphisms (SNPs), including one that predicts aVal366Ala substitution, and an 8 base-pair (bp) insertion/deletion. Ourexpression studies revealed the presence of the transcript in various humantissues including pancreas, and two major insulin-responsive tissues: fat andskeletal muscle. The characterization of the KCNJ9 gene should facilitate furtherstudies on the function of the KCNJ9 protein and allow evaluation of thepotential role of the locus in Type II diabetes.BACKGROUND: At present, it is one of the most important issues for the treatment of breast cancer to develop the standard therapy for patients previously treated with anthracyclines and taxanes. With the objective of determining the usefulnessof vinorelbine monotherapy in patients with advanced or recurrent breast cancerafter standard therapy, we evaluated the efficacy and safety of vinorelbine inpatients previously treated with anthracyclines and taxanes.").toDF("text")
val result = pipeline.fit(data).transform(data)
```


{:.nlu-block}
```python
import nlu
nlu.load("en.med_ner.drugs").predict("""The human KCNJ9 (Kir 3.3, GIRK3) is a member of the G-protein-activated inwardly rectifying potassium (GIRK) channel family. Here we describe the genomicorganization of the KCNJ9 locus on chromosome 1q21-23 as a candidate gene forType II diabetes mellitus in the Pima Indian population. The gene spansapproximately 7.6 kb and contains one noncoding and two coding exons separated byapproximately 2.2 and approximately 2.6 kb introns, respectively. We identified14 single nucleotide polymorphisms (SNPs), including one that predicts aVal366Ala substitution, and an 8 base-pair (bp) insertion/deletion. Ourexpression studies revealed the presence of the transcript in various humantissues including pancreas, and two major insulin-responsive tissues: fat andskeletal muscle. The characterization of the KCNJ9 gene should facilitate furtherstudies on the function of the KCNJ9 protein and allow evaluation of thepotential role of the locus in Type II diabetes.BACKGROUND: At present, it is one of the most important issues for the treatment of breast cancer to develop the standard therapy for patients previously treated with anthracyclines and taxanes. With the objective of determining the usefulnessof vinorelbine monotherapy in patients with advanced or recurrent breast cancerafter standard therapy, we evaluated the efficacy and safety of vinorelbine inpatients previously treated with anthracyclines and taxanes.""")
```

</div>

## Results

```bash
+-----------------+---------+
|chunk            |ner      |
+-----------------+---------+
|potassium        |DrugChem |
|anthracyclines   |DrugChem |
|taxanes          |DrugChem |
|vinorelbine      |DrugChem |
+-----------------+---------+
```

{:.model-param}
## Model Information

{:.table-model}
|---|---|
|Model Name:|ner_drugs|
|Compatibility:|Spark NLP for Healthcare 3.0.0+|
|License:|Licensed|
|Edition:|Official|
|Input Labels:|[sentence, token, embeddings]|
|Output Labels:|[ner]|
|Language:|en|

## Data Source

Trained on i2b2_med7 + FDA with 'embeddings_clinical'.
https://www.i2b2.org/NLP/Medication

## Benchmarking

```bash
|    | label         |    tp |    fp |    fn |     prec |      rec |       f1 |
|---:|:--------------|------:|------:|------:|---------:|---------:|---------:|
|  0 | B-DrugChem    | 32745 |  1738 |   979 | 0.949598 | 0.97097  | 0.960165 |
|  1 | I-DrugChem    | 35522 |  1551 |   764 | 0.958164 | 0.978945 | 0.968443 |
|  2 | Macro-average | 68267 |  3289 |  1743 | 0.953881 | 0.974958 | 0.964304 |
|  3 | Micro-average | 68267 |  3289 |  1743 | 0.954036 | 0.975104 | 0.964455 |
```